Good patent news for Lilly, Pfizer and Sanofi-Aventis
The end of 2006 saw: the US Court of Appeals for the Federal Circuit in Washington DC uphold Eli Lilly's Zyprexa (olanzapine) patent expiring in 2011; a Chinese court, Beijing No 1 Intermediate Court, protect the validity of Pfizer's Viagra (sildenafil) patent in that country, ordering two local drugmakers, Lianhuan Pharmaceuticals and Beijing Health New Concept to stop selling the erectile dysfunction drug and pay Pfizer around $38,000 in damages; and a Canadian Federal Court of Appeals rule in favor of French drug major Sanofi-Aventis' Plavix (clopidogrel) patent, which was challenged by Apotex.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze